<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03512236</url>
  </required_header>
  <id_info>
    <org_study_id>CT031-ADO09</org_study_id>
    <nct_id>NCT03512236</nct_id>
  </id_info>
  <brief_title>A Trial to Investigate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BioChaperone® Pramlintide Insulin in Patients With Type 1 Diabetes Mellitus</brief_title>
  <official_title>A Trial to Investigate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BioChaperone® Pramlintide Insulin in Patients With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adocia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adocia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, randomised, double-blind, active comparator controlled, three-period
      cross-over, single dose trial in subjects with type 1 diabetes mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center, randomised, double-blind, active comparator controlled, three-period
      cross-over, single dose trial in subjects with type 1 diabetes mellitus.

      Each subject will be randomly allocated to a sequence of three treatments:(i) simultaneous
      administrations of BioChaperone® pramlintide human insulin (BC Pram Ins) and placebo, (ii)
      simultaneous injections of pramlintide (Symlin®) and human insulin (Humulin®) and (iii)
      simultaneous injections of insulin lispro (Humalog®) and placebo.

      Subjects will come in a fasted state to the clinical trial centre in the morning, meal test
      procedures will be performed and subjects will stay at the clinical trial centre until the
      post-dose follow-up period has been terminated.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 27, 2018</start_date>
  <completion_date type="Anticipated">October 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CmaxPram</measure>
    <time_frame>From 0 to 8 hours</time_frame>
    <description>Maximum pramlintide concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCPram_0-8h</measure>
    <time_frame>From 0 to 8 hours</time_frame>
    <description>Area Under the pramlintide concentration-time Curve from 0-8 hours after IMP administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of pramlintide</measure>
    <time_frame>From 0 to 8 hours</time_frame>
    <description>Area Under the pramlintide concentration-time Curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of insulins</measure>
    <time_frame>From 0 to 8 hours</time_frame>
    <description>Area Under the insulin concentration-time Curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose pharmacodynamics</measure>
    <time_frame>From 0 to 8 hours</time_frame>
    <description>Area Under the blood glucose concentration-time Curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability (Adverse Events recording)</measure>
    <time_frame>From 0 to 8 hours</time_frame>
    <description>Number of adverse events</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>BC Pram Ins</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous injection of BC Pram Ins + injection of placebo (0.9% NaCl) to ensure the double dummy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Symlin® and Humulin®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Simultaneous subcutaneous injections avec pramlintide and human insulin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Humalog®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single subcutaneous injection of lispro + injection of placebo (0.9% NaCl) to ensure the double dummy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BC Pram Ins</intervention_name>
    <description>Injection of BC Pram Ins</description>
    <arm_group_label>BC Pram Ins</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Symlin® and Humulin®</intervention_name>
    <description>Injection of pramlintide and human insulin</description>
    <arm_group_label>Symlin® and Humulin®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Humalog®</intervention_name>
    <description>Injection of lispro</description>
    <arm_group_label>Humalog®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Injection of 0.9% NaCl</description>
    <arm_group_label>BC Pram Ins</arm_group_label>
    <arm_group_label>Humalog®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects aged 18-64 years (both inclusive)

          -  Type 1 diabetes mellitus (as diagnosed clinically) ≥ 12 months

          -  Treated with multiple daily insulin injections ≥ 12 months

          -  Treated with an evening dose of once-daily insulin glargine U100 at screening

          -  Fasting C-peptide ≤ 0.30 nmol/L

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to IMPs, paracetamol (acetaminophen) or related
             products

          -  Type 2 diabetes mellitus

          -  Clinically significant abnormal haematology, biochemistry, or urinalysis screening
             tests, as judged by the Investigator considering the underlying disease

          -  Presence of clinically significant acute gastrointestinal symptoms (e.g. nausea,
             vomiting, heartburn or diarrhoea), as judged by the Investigator

          -  Known slowing of gastric emptying, including gastroparesis, and or gastrointestinal
             surgery that in the opinion of the investigator might change gastrointestinal motility
             and food absorption

          -  Intake of medication known to affect gastrointestinal motility, including but not
             limited to erythromycin, metoclopramide, cisapride, cholestyramine or colestipol
             within 4 weeks before screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grit Andersen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profil Institut für Stoffwechselforschung GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bianca Schmidt</last_name>
    <phone>+49.21314018 0</phone>
    <email>regulatory@profil.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Profil Institut für Stoffwechselforschung GmbH</name>
      <address>
        <city>Neuss</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bianca Schmidt</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2018</study_first_submitted>
  <study_first_submitted_qc>April 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2018</study_first_posted>
  <last_update_submitted>April 19, 2018</last_update_submitted>
  <last_update_submitted_qc>April 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Pramlintide</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
    <mesh_term>Islet Amyloid Polypeptide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

